Biotech RadarJobs updated

COMPANY

Enliven Therapeutics

HQ: Burlingame, CA source · enliventherapeutics.com ↗ · West Coast

Clinical Phase 1

Location: Burlingame, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: HER2 Amplification Chronic Myeloid Leukemia Cml HER2-positive Breast Cancer HER2-positive Gastric Cancer HER2 Positive Solid Tumors Colorectal Cancer HER2 Mutant Non-small Cell Lung Cancer HER2-positive Metastatic Breast Cancer HER2 Gene Mutation CML (Chronic Myelogenous Leukemia) ELVN-001 ELVN-002

$600.0MRaised (2 yrs)4Trials (company is sponsor)

Timeline

  1. Raise Follow-on offering: $400M (total, as published), announced Jun 11, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering: $200M (total, as published), announced Jun 13, 2025. Source: SEC filing. source ↗
  3. Trial start Phase 1: ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants source ↗
  4. Trial start Phase 1: ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer source ↗
  5. Trial start Phase 1: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer source ↗
  6. Trial start 1: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $600.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT05304377A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia1RecruitingMay 22, 20222027-12 (estimated)
NCT06328738ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerPhase 1Active, not recruitingMay 30, 20242027-01 (estimated)
NCT05650879ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerPhase 1Active, not recruitingMar 20, 20232026-07 (estimated)
NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsPhase 1RecruitingJan 23, 20252028-01 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback